| Description | This is anti-human antagonistic antibody against GIPR. The antibody effectively blocks the C terminus of the GIP peptide, preventing the interaction between GIP and GIPR ECD. Anti-GIPR antagonistic antibodies show promise as a potential therapeutic approach for treating obesity. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Epitope | GIPR ECD |
| Neutralization Mechanism | Antagonized human GIPR activity by inhibiting GIP-induced cAMP production in cells expressing GIPR. |
| IC50 | 23.8 nM (human GIPR) 15.1 nM (nonhuman primate GIPR) |
| Affinity | KD = 61 pM (human GIPR) |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | Block; FuncS |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
